The Management Board of SCOPE FLUIDICS S.A. seated in Warsaw hereby publicly announces that on 30th July 2018 SCOPE FLUIDICS S.A. concluded an agreement with Clairfield Partners LLC seated in New York (hereinafter referred to as “the Consultant”), under which consulting services will be provided regarding obtaining of a strategic investor interested in the purchase of the shares of a special purpose entity (Curiosity Diagnostics Sp. z o.o.). Curiosity Diagnostics Sp. z o.o. developed the PCR|ONE diagnostic system for rapid infection detection. According to Company’s schedule, approval for commercial marketing of the PCR|ONE system and its sale to a global manufacturer of med-tech devices is planned to take place in 2020.
Responsibilities of Clairfield will include identification and selection of potential buyers and making them interested in the PCR|ONE system. The activities will entail e.g. drawing-up necessary documents and establishing contacts with global companies operating in the healthcare sector. During the next stage, Clairfield will support the Company in the organization of the due diligence process and shaping negotiation strategy, as well as in final negotiations on the shape of the agreement on the sale of shares of Curiosity Diagnostics Sp. z o.o
Consulting services will be provided on the basis of exclusivity. Remuneration for delivery of the services includes a variable component – a so-called success fee, dependant on the results obtained (i.e. sales value) and a fixed component, divided into several payments.
The above information was made public due to the fact that the performance of the services under the agreement concluded with Clairfield may have in the future a significant influence on the valuation of Company’s assets and its financial situation. In line with the dividend policy stipulated in the Company’s Articles of Association, at least a half of the money acquired from the sale of shares of Curiosity Diagnostics Sp. z o.o. will be paid out to the shareholders of Scope Fluidics.
Clairfield is an international company which provides corporate finance services (mainly related to mergers and acquisitions) to international corporations and financial investors. The Consultant focuses on mid-market companies and operates the transactions of up to EUR 500,000,000 enterprise value. In 2018, the company was listed as one of the top ten European financial advisors in Thomson Reuters EMEA Mid-Market League Tables. In 2017, the company concluded 110 transactions. The value of transactions concluded by the Consultant over the last five years was ca. USD 23 billion.
In the healthcare market sector, Clairfield develops its competencies in the fields of biotechnology, pharmacy, medical devices and supplies, hospitals, clinics, laboratory devices and services. As far as the biotechnology projects and medical devices are concerned, the Consultant has a substantial experience in the diagnostics and molecular therapeutics sector. Thanks to its relationships in the aforementioned market sectors, Clairfield is able to monitor the market on an ongoing basis and use information on key market events.
